Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it drew down US$50 million from its five-year facility provided…









